TW202323275A - 預防及治療突觸核蛋白病的方法 - Google Patents

預防及治療突觸核蛋白病的方法 Download PDF

Info

Publication number
TW202323275A
TW202323275A TW111133232A TW111133232A TW202323275A TW 202323275 A TW202323275 A TW 202323275A TW 111133232 A TW111133232 A TW 111133232A TW 111133232 A TW111133232 A TW 111133232A TW 202323275 A TW202323275 A TW 202323275A
Authority
TW
Taiwan
Prior art keywords
syn
lys
seq
cell epitope
peptide
Prior art date
Application number
TW111133232A
Other languages
English (en)
Chinese (zh)
Inventor
珍 科斯梅 多達特
Original Assignee
美商瓦辛尼帝股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商瓦辛尼帝股份有限公司 filed Critical 美商瓦辛尼帝股份有限公司
Publication of TW202323275A publication Critical patent/TW202323275A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW111133232A 2021-09-01 2022-09-01 預防及治療突觸核蛋白病的方法 TW202323275A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163239505P 2021-09-01 2021-09-01
US63/239,505 2021-09-01

Publications (1)

Publication Number Publication Date
TW202323275A true TW202323275A (zh) 2023-06-16

Family

ID=85413127

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111133232A TW202323275A (zh) 2021-09-01 2022-09-01 預防及治療突觸核蛋白病的方法

Country Status (10)

Country Link
US (1) US20240358806A1 (cg-RX-API-DMAC7.html)
EP (1) EP4395894A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024534901A (cg-RX-API-DMAC7.html)
KR (1) KR20240055785A (cg-RX-API-DMAC7.html)
CN (1) CN118119403A (cg-RX-API-DMAC7.html)
AU (1) AU2022337284A1 (cg-RX-API-DMAC7.html)
CA (1) CA3230300A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024002684A (cg-RX-API-DMAC7.html)
TW (1) TW202323275A (cg-RX-API-DMAC7.html)
WO (1) WO2023034914A2 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025137102A1 (en) * 2023-12-18 2025-06-26 Vaxxinity, Inc. Peptide immunogen compositions and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6906169B2 (en) * 2001-05-25 2005-06-14 United Biomedical, Inc. Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
EP1572894B1 (en) * 2001-11-21 2016-04-13 New York University Synthetic immunogenic but non-deposit-forming polypeptides and peptides homologous to amyloid beta, prion protein, amylin, alpha synuclein, or polyglutamine repeats for induction of an immune response thereto
US8697082B2 (en) * 2002-11-01 2014-04-15 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
GB201512203D0 (en) * 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
JP2021508672A (ja) * 2017-06-16 2021-03-11 ユナイテッド ニューロサイエンスUnited Neuroscience シヌクレイノパチーの治療のためのアルファ−シヌクレインタンパク質のc末端からのペプチド免疫原及びその製剤

Also Published As

Publication number Publication date
AU2022337284A1 (en) 2024-03-21
US20240358806A1 (en) 2024-10-31
KR20240055785A (ko) 2024-04-29
MX2024002684A (es) 2024-05-16
EP4395894A4 (en) 2025-08-06
CA3230300A1 (en) 2023-03-09
WO2023034914A3 (en) 2023-04-13
CN118119403A (zh) 2024-05-31
EP4395894A2 (en) 2024-07-10
JP2024534901A (ja) 2024-09-26
WO2023034914A2 (en) 2023-03-09

Similar Documents

Publication Publication Date Title
US9102752B2 (en) Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer's type
JP5558834B2 (ja) シヌクレイノパチーおよびアミロイド形成疾患(amyloidogenicdisease)の予防および処置
US20240150419A1 (en) Tau peptide immunogen constructs
JP4899037B2 (ja) Synuclein病の予防および治療
JP2025090637A (ja) シヌクレイノパチーの治療のためのアルファ-シヌクレインタンパク質のc末端からのペプチド免疫原及びその製剤
TW202438516A (zh) TAU及β類澱粉肽免疫原組合物及相關方法
CN116261464A (zh) 免疫原性化合物
US20240358806A1 (en) Methods for the prevention and treatment of synucleinopathies
JP2023519104A (ja) 凝集膵島アミロイドポリペプチド(iapp)と関連する障害を予防及び治療するための、iappを標的とするペプチド免疫原
US20220023401A1 (en) Peptide vaccine for prevention and immunotherapy of dementia of the alzheimer's type
JP2025523036A (ja) タウペプチド免疫原コンストラクト
RU2798972C2 (ru) Тау-пептидные иммуногенные конструкции
HK40022726A (zh) Tau肽免疫原构建体